Sign In
Buy CADL
$8.80
+0.380 (+4.51%)
At Close: Jun 03, 2026
Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling
10:23am, Tuesday, 21'st Apr 2026
Candel Therapeutics, Inc. seems positioned for significant upside as its lead asset, aglatimagene, nears key prostate cancer Phase 3 readouts and a potential BLA filing. CADL's aglatimagene has demons
Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating
02:08pm, Monday, 20'th Apr 2026
That timing matters. The tape is conflicted: the Nasdaq (QQQ) is down 0.53% and the S&P 500 (SPY) is down 0.35%, while the Russell 2000 (IWM) is up 0.28%.
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 02'nd Apr 2026
NEEDHAM, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologi
Candel Therapeutics, Inc. (NASDAQ:CADL) Receives $18.00 Average Target Price from Brokerages
01:31am, Saturday, 21'st Mar 2026
Shares of Candel Therapeutics, Inc. (NASDAQ: CADL - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight research firms that are presently covering the stock, Marke
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409
09:45am, Tuesday, 17'th Mar 2026
Candel Therapeutics Inc (NASDAQ:CADL) has reported updated clinical data showing extended survival outcomes from its ongoing phase 2a trial of aglatimagene besadenovec (CAN-2409) in patients with adva
Goldman Sachs says the era of low hiring and low firing is here to stay, and that may be good news
08:08am, Tuesday, 17'th Mar 2026
The bank's economists argue that what looks like a fragile jobs market is actually a sign that workers and employers have gotten much better at finding each...
NEEDHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot
Dell shrinks workforce by 11,000 in fiscal 2026 amid ongoing restructuring
07:33am, Tuesday, 17'th Mar 2026
Dell Technologies Inc (NASDAQ:DELL) reduced its workforce by roughly 11,000 employees in fiscal 2026, bringing total headcount to about 97,000 as of January...
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409
05:39am, Tuesday, 17'th Mar 2026
Candel Therapeutics Inc (NASDAQ:CADL) has reported updated clinical data showing extended survival outcomes from its ongoing phase 2a trial of aglatimagene...
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances
09:39am, Thursday, 12'th Mar 2026
Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential commercialization, outlining new phase 3 trials and a planned regulatory filing while r
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
08:05am, Thursday, 12'th Mar 2026
NEEDHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot
JPMorgan sees 40% upside in Hochschild as gold surge powers bumper earnings outlook
08:01am, Thursday, 12'th Mar 2026
Hochschild Mining PLC (LSE:HOC, OTCQX:HCHDF, FRA:H3M), the FTSE 250 precious metals producer, rose 4% to 674p on Thursday after JPMorgan upgraded the stock...
Nasdaq leads Wall St lower as oil prices spike on Iran revenge strikes
05:55am, Thursday, 12'th Mar 2026
9.55am: Stocks open lower, led by Nasdaq US stocks opened lower as oil prices spiked north again. The Dow Jones dropped almost 600 points or 1.2% in...
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances
05:33am, Thursday, 12'th Mar 2026
Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential commercialization, outlining new phase 3...
NEEDHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologi
